# A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

> **NCT03952078** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Corvus Pharmaceuticals, Inc.** · enrollment: 151 (estimated)

## Conditions studied

- T-cell Lymphoma

## Interventions

- **DRUG:** CPI-818

## Key facts

- **NCT ID:** NCT03952078
- **Lead sponsor:** Corvus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-03
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 151 (ESTIMATED)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03952078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03952078, "A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03952078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*